CSA eye drops potentially useful for SEI treatment after AK

Article

Cycloisporine A (CSA) 1% eye drops could be an effective corticosteroid-sparing agent for treating symptomatic corneal subepithelial infiltrates (SEI) after adenoviral keraconjunctivitis (AK).

Cyclosporine A (CSA) 1% eye drops could be an effective corticosteroid-sparing agent for treating symptomatic corneal subepithelial infiltrates (SEI) after adenoviral keraconjunctivitis (AK), claims a paper featured in Cornea.

A retrospective case series led by Dr Bennie Jeng, Department of Ophthalmology, University of California, San Francisco, California, USA, included patients with symptomatic corneal SEI occurring after AK from 2 institutions. All patients were resistant to tapering of corticosteroid eye drops prior to administration of CSA drops.

Basic demographic data, involved eyes, duration of symptoms, initial best spectacle-corrected visual acuity (BSCVA), types of corticosteroid administered, clinical course and best spectacle-corrected visual acuity at the final follow-up visit.

Symptomatic SEI after AK, that was resistant to tapering but responsive to corticosteroid eye drops, was found in 12 eyes of 7 patients. The corticosteroid eye drops could be tapered after the administration of CSA eye drops.

It was found that all eyes could generally be maintained on CSA drops for once a day or less. However, the research suggests further study into the use of CSA drops in treating SEI.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.